The shares gained 31.60 francs and are up 74% over the past year. Tecan said Thursday that third-quarter sales increased 6.9% and order entry rose 3.1%, both measured in local currencies. Sales in its life-sciences business grew 5.6%, while the partnering business unit recorded 7.8% growth.

The company now expects full-year sales to rise by a low- to mid-single-digit percentage, compared with its previous forecast of low-single-digit growth. Sales in 2025 were 882.5 million Swiss francs ($1.08 billion).

Tecan also raised its outlook for adjusted earnings before interest, taxes, depreciation and amortization margin to 16.5% to 16.8%, from a previous range of 15.5% to 16.5%. The adjusted Ebitda margin in 2025 was 16.1%.